You searched for Antibody candidate - Page 62 of 69

Best in Biotech 10 Jun 2019

The 10 Biotech Companies in London to Keep an Eye on in 2019

…in the city, these are the 10 biotech companies in London you need to know. Founded in 2015, Orchard Therapeutics is developing multiple gene therapy candidates to treat rare genetic…

June 10, 2019 - 5 minutesmins - By Clara Rodríguez Fernández

Opinion 12 Dec 2022

Artificial intelligence: a new era in rare genetic disease diagnosis

…candidate variants in undiagnosed genetic disorders and better inform healthcare professionals. By quickly identifying the most promising candidate variants for interpretation, AI-driven tools are revolutionary, supporting experts in making fast,…

December 12, 2022 - 6 minutesmins - By External Contributor

In Depth 14 May 2025

The stem cell race for Parkinson’s disease: Recent studies show significant promise

…from the U.S. Food and Drug Administration (FDA) to progress the candidate in January 2025. This came after the candidate, which is made up of immature brain cells called dopaminergic…

May 14, 2025 - 8 minutesmins - By Willow Shah-Neville

In Depth 15 Aug 2023

Can stem cell treatment repair damaged knees?

…the hyperbaric oxygen chamber is to encourage stem cells to produce capillaries and blood vessels. Is stem cell therapy a worthy candidate to target knee arthritis? Meanwhile, knee arthritis (osteoarthritis)…

August 15, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 28 Jan 2025

ITM-11 succeeds in phase 3: The first big win for radiopharma?

…more and more investment and candidates are showing great promise, the field still awaits its first big win. The COMPETE trial is the first to show that a targeted radiopharmaceutical…

January 28, 2025 - 9 minutesmins - By Jules Adam

News and Trends 17 Oct 2017

Genfit Gets €180M Cash Injection to Bring its Pipeline to Market

Elafibranor, Genfit’s lead candidate, will continue its march towards the market with the added boost of massive financial support. Genfit is a leader in the development of diagnostic tools and…

October 17, 2017 - 3 minutesmins - By Alex Dale

In Depth 27 Jun 2025

Psychedelics sans side effects: neuroplastogens gain ground

…in neuropsychiatry. With its lead candidate in the Investigational New Drug (IND)-enabling stage, the Washington-based startup hopes to head to the clinic to treat depression and PTSD soon. As about…

June 27, 2025 - 8 minutesmins - By Roohi Mariam Peter

News and Trends 7 Mar 2016

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Akinion (Sweden) will stop the development of its candidate for leukemia, after patients in phase I/II have experienced liver toxicity. As a result, main investor Karolinska Development takes an €8M…

March 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 19 Apr 2017

UPDATE: Verona sets terms & dials back its IPO goal to a still-hefty €75M

…its lead candidate RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). The company also announced the dosing of the first patient for its new…

April 19, 2017 - 3 minutesmins - By Melanie De Almeida

Best in Biotech 17 Aug 2023

Six Toronto-based biotech companies to watch this year

…like Deep Genomics having developed a portfolio of candidates, some of which are being evaluated as therapies for central nervous system (CNS)-related disorders, the city’s research and development sector is…

August 17, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 17 Feb 2016

After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie

Galapagos (Belgium) is moving forward with their cystic fibrosis drug candidate after promising Phase I results – and still in collaboration with AbbVie (US). Curiouser and curiouser… Galapagos is one…

February 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

epigenetics review cambridge epigenetix oryzon1

In Depth 5 Sep 2017

The Next Generation of Genetic Medicine: A Review of Epigenetics

…that patient stratification is not an option. A German company, 4SC, has taken heed of such findings, combining its lead candidate resminostat with Bayer’s kinase inhibitor, Nexavar (sorafenib). In January,…

September 5, 2017 - 9 minutesmins - By Evelyn Warner

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Antibody candidate

The 10 Biotech Companies in London to Keep an Eye on in 2019

Artificial intelligence: a new era in rare genetic disease diagnosis

The stem cell race for Parkinson’s disease: Recent studies show significant promise

Can stem cell treatment repair damaged knees?

ITM-11 succeeds in phase 3: The first big win for radiopharma?

Genfit Gets €180M Cash Injection to Bring its Pipeline to Market

Psychedelics sans side effects: neuroplastogens gain ground

Swedish Investment loses €8M over failed Phase I/II for Leukemia

UPDATE: Verona sets terms & dials back its IPO goal to a still-hefty €75M

Six Toronto-based biotech companies to watch this year

After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie

The Next Generation of Genetic Medicine: A Review of Epigenetics

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!